Search

everythinglearnresearchcommunity

for

Search:↓

Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.

Finasteride metabolites found in pigs match human studies, making pigs a valid model for human drug research.

The document concludes that a compound with potential for treating prostate cancer and hair loss was successfully made and its detailed structure was confirmed.

Genetic profiling can improve androgenetic alopecia treatment by predicting drug response and minimizing side effects.

Three compounds were found to inhibit a prostate disease-related enzyme and reduce prostate size more effectively than the current treatment, suggesting they could be used for treating benign prostatic hyperplasia.

Plant-based compounds may offer safer prostate cancer treatment with fewer side effects.

The ABI1 gene contributes to prostate cancer progression and treatment resistance.

Finasteride, a drug that changes testosterone to a different hormone, was studied and its effects over time were modeled successfully.

The human type II 5α-reductase gene, linked to certain male health conditions, has a specific structure and low similarity to other related genes.

The structure of SRD5A reveals how it reduces steroids, aiding drug design for related health conditions.

DA-9401 helps protect rat testis from finasteride damage.

A woman's severe male hormone excess was caused by a small, hard-to-find ovarian tumor.

New A-homo-B, 19-dinor steroids showed strong antiandrogenic activity without affecting the enzyme 5α-reductase or androgen receptor binding.

Finasteride may improve prostate cancer therapy by enhancing testosterone's benefits and reducing risks.

Mutations at Val-889 and Arg-752 disrupt key interactions in androgen receptor dimerization.

The new progesterone derivatives effectively inhibit 5α-reductase and bind to the androgen receptor.

Finasteride helps female-pattern hair loss.

The enzyme 5α-reductase type 1 is important for blood vessel development and fertility in the uterus.

Using hair loss drugs finasteride and dutasteride may cause sexual side effects.

Prostate-specific antigen may be a new marker for excess male hormones in women with polycystic ovary syndrome.

Five new mutations in the androgen receptor gene were found, helping to understand androgen insensitivity syndrome better.

Tamoxifen may cause female hair loss by increasing androgen receptor expression.

The document suggests that targeting the hormone DHT could be a more effective treatment for prostate cancer than targeting testosterone.

New pregnane derivatives are effective at inhibiting an enzyme linked to hair loss and reducing oil gland activity.

The method accurately measures cyproterone acetate in plasma, showing no significant difference between two formulations.

The gene SDR5A1 is found in scalp hair of both hirsute and normal individuals, but it does not explain differences in hair growth.

Bioengineered nanoparticles can effectively treat hair loss by targeting specific enzymes and receptors.

Androgen receptors in the mouse brain may explain cognitive and mood changes in prostate cancer treatment.